

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Terrance D. Barrett et al

Serial No. : 10/612,150

Art Unit:

Filed

: July 2, 2003

Examiner:

For

: CCK-1 Receptor Modulators

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

September 30, 2003
(Date of Deposit)

John W. Harbour (Name of applicant, assignee, or Registered Representative)

(Signature)

September 30, 2003

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information \boxtimes Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with [] the first or _second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10- \Box / the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of: Statement in Accordance with §1.97(e) (attached); or

0750/ / the fee of $$180.00$ as set forth
in §1.17(p).
In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in §1.17(p).
☐ Copies of each of the references listed on the
attached Form PTO-1449 are enclosed herewith.
attached Form F10-1449 die cherebed merewren
Copies of references listed on the attached Form PTO-
1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references
[list as appropriate], and the likelihood that
these references are available to the Examiner,
copies are not enclosed herewith.
If any of the foregoing publications are not
<pre>If any of the foregoing publications are not available to the Examiner, Applicant will</pre>
available to the Examiner, Applicant will
available to the Examiner, Applicant will endeavor to supply copies at the Examiner's
available to the Examiner, Applicant will endeavor to supply copies at the Examiner's
available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request. Copies of only foreign patent documents and non-
available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request. Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98
available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request. Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a) (2). (The U.S. patents and each U.S. patent application

•

national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i). There are no listed references which are not in the \boxtimes English language. The relevance of those listed references which are not in the English language is as follows: Attached are copies of search report(s) from П corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D. Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D. Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD0016NP/JWH. This form is submitted in triplicate. Respectfully submitted, John W. Harbour Reg. No. 31,365 Attorney for Applicants Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2169 DATED: September 30, 2003

Under the Paperno...
Substitute for form 1449A/PTO

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

a collection of information unless it displays a	a valid OMB control number.
Application Number	10/612,150
Filing Date	July 2, 2003
First Named Inventor	Terrance D. Barrett
Group Art Unit	
Examiner Name	
Attorney Docket Number	PRD 0016 NP

				U.S. PATENT DOCUMENTS		
Examiner Initials	Cite No.1	U.S. Patent Doo	cument	Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines,
		Number	Kind Code ² (if known)	of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appea
		4,826,868		Wachter, M.P. and Ferro, M.P.	05-02-1989	
		5,051,518		Murray, W.V. and Wachter, M.P.	09-24-1991	
		5,164,381		Wachter, M.P. and Ferro, M.P.	11-17-1992	
			100			
	+					

			FORE	IGN PATENT DOCUMENTS			_
Examiner Cite Initials No.1	Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages or relevant	
	 Office ³	Number ⁴	KindCode ⁵	Applicant of Cited Document		figures appear	T ⁶
	wo	97/11704	A1	G.D. Searle & Company	04-03-1997		<u> </u>
	wo	01-66539	A1	Smithkline Beecham P.L.C.	09-13-2001		ऻ
	wo	01-85723	A1	James Black Foundation Limited	11-15-2001		<u> </u>
	wo	01-85724	A1	James Black Foundation Limited	11-15-2001		<u> </u>
	wo	01-90078	A1	James Black Foundation Limited	11-29-2001		ــــــ
	EP	0293220	B1	Ortho Pharmaceutical Corporation	08-31-1994		

E	Date
Examiner	Considered
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450 1450, Alexandria, VA 22313-1450

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. e Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE of a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

a collection of information unless it displays a	Valid OMB control flufficer.
Application Number	10/612,150
Filing Date	July 2, 2003
First Named Inventor	Terrance D. Barrett
Group Art Unit	
Examiner Name	
Attorney Docket Number	PRD 0016 NP
•	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	
Examiner's	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
inuais	140.	GIGOUX, V. et al. Arginine 336 and Asparagine 333 of the Human Cholecystokinin-A Receptor Binding Site Interact with the	
		HARPER, E.A. et al. Analysis of Variation in L-365,260 Competition Curves in Radioligand Binding Assays. Br. J. Pharmacol 1996, 118:1717–1726	
		HULL, R.A. et al. 2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP) — A Selective Cholecystokinin CCKA-	
		KLAPARS, A. et al. A General and Efficient Copper Catalyst for the Amidation of Aryl Halides and the N-Arylation of	
		KLAUSNER, Y.S. and BODANSZKY, M. The Azide Method in Peptide Synthesis: Its Scope and Limitations. Synthesis 1974, 8:549–559	
		MORADI, W.A. and BUCHWALD, S.L. Palladium-Catalyzed alpha-Arylation of Esters. J. Am. Chem. Soc. 2001, 123(33):7996–8002	
		MORTON, M.F. et al. Pharmacological Comparison of the Alternatively Spliced Short and Long CCK2 Receptors. Br. J. Pharmacol. 2003, 140(1):218–224	
		MURRAY, W.V. et al. Synthesis of 3-(1,5-Diphenyl-3-pyrazolyl)aryl Propanates. J. Heterocycl. Chem. 1990, 27:1933–1940 PENNING, T.D. et al. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 1997, 40(9):1347–1365	
		SAITO T, et al. Total Synthesis of the Euraquinocins, J. Am. Chem. Soc. 1998, 120(45):11633–11644	
		SHEN, DM. et al. Versatile and Efficient Solid-Phase Syntheses of Pyrazoles and Isoxazoles. Organic Letters 2000, 2(18):2789–2792	
		TULLIO, P. et al. Therapeutic and Chemical Developments of Cholecystokinin Receptor Ligands. Exp. Opin. Invest. Drugs 2000, 9(1):129–146	
		WANG 7 et al. A New Synthesis for Methyl 2-Benzyloxyphenylacetate. Synth. Commun. 1999, 29(13):2361–2364	
		WOLFE, J.P. et al. Simple Efficient Catalyst System for the Palladium-Catalyzed Amination of Aryl Chlorides, Bromides, and Triflates. J. Org. Chem. 2000, 65(4):1158–1174	
	+		

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.